Many global health professionals have dreamed about solving drug shortages, and St. Jude Children’s Research Hospital is taking the first steps toward eliminating the problem, said Carlos Rodriguez-Galindo, director of St. Jude Global.
The acquisition of Cancer Treatment Centers of America will allow City of Hope to build a national network of cancer centers that is fundamentally different from those of other cancer centers.
After having treated over 200,000 COVID cases over two years—more than any health system in the U.S.—Northwell Health once again finds itself in the center of the storm as cases of the omicron variant escalate in New York State.
To accurately gauge the impact of the National Cancer Act of 1971 at the half-century point, Abbe R. Gluck and Charles S. Fuchs decided to focus on more than the science of cancer.
DEI Network founders: Let’s work together to increase diversity across all cancer centers in America
Christopher Li and Wendy Law, both of Fred Hutchinson Cancer Research Center, have a message for leaders of DEI programs in oncology.
Soon after starting work on a book about the role the NCI-designated cancer centers have played in the National Cancer Program, Skip Trump and Eric Rosenthal got in touch with John W. Yarbro.
The University of Virginia has taken a long, circuitous path to NCI comprehensive cancer center designation, but it got there.
The National Coalition for Cancer Survivorship began in 1986 with 23 people at a hotel in Albuquerque and a $100 contribution from Patricia A. Ganz, who recalls thinking: “I don’t think I’ve ever invested in anything that was so good.”
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
